HeartSciences Inc
HSCS
View Detailed Chart
3.490USD
-0.030-0.85%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
7.96MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.85%
5 Days
+16.14%
1 Month
-2.79%
6 Months
+15.18%
Year to Date
-8.64%
1 Year
+12.94%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a good stock market performance and outperforming fundamentals, the technicals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
13.500
Target Price
+283.52%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.35K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 37.94.
Fairly Valued
The company’s latest PE is -0.37, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 134.20K shares, decreasing 15.52% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.32K shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.
Ticker SymbolHSCS
CompanyHeartSciences Inc
CEOMr. Andrew Simpson
Websitehttps://heartsciences.com/
Related Instruments
-0.32%
+0.66%
-0.41%
-1.01%
-0.46%
-0.19%
-0.04%
-1.02%
+1.23%
-0.64%
-1.80%
-0.27%
-2.84%
-1.19%
-0.78%
-0.30%
+0.98%
-0.72%
-1.25%
-3.23%
